Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Next generation transparent solar windows based on customised integrated photovoltaics (Solar-Win)

Framework: Horizon 2020 — Industrial Leadership
Action type: Innovation actions
Countries involved: Spain,Austria,Spain,Netherlands
Call: Fast Track to Innovation (FTI) (H2020-EIC-FTI-2018-2020, 2019)
Start date: 2019-10-01
End date: 2021-12-31
Duration (months): 27.0
Total project cost (EUR): 3095812.5
EU funding (EUR): 2419593.75
Participants: 4
Project status: CLOSED

The main goal of Solar-Win is the industrial scale-up, validation under real-world operation conditions (TRL8) and commercialisation of next generation transparent and non-intrusive photovoltaic (PV) windows. The project will result in a unique transparent and electricity-generating window that merges the functionality of a PV module and a window in one, allowing a strong increase in the surface available in the building for generation of PV electricity. Solar-Win will revolutionize the Building Integrated PV (BIPV) and the architectural sectors, by providing a PV window solution featuring a unique set of characteristics, namely: (1) transparent and visually non-intrusive windows (with controlled visible transparency from 40% to 75%) able to generate up to 30 W/m2 of green electricity; (2) full compatibility with existing window manufacturing technologies; (3) lifespan equivalent to standard windows (20 years); and (4) cost effectiveness (cost increase of just 30% with respect to a standard window). To achieve these goals, solar-Win involves two Technology-based SMEs (PHYSEE and SUNPLUGGED from the Smart Window and PV sectors, respectively) coordinated by a flagship RTD organisation with a strong experience and background in technology transfer and optimisation of advanced PV technologies (IREC) and a leader constrution company (ACCIONA) which is the main costumer segment. The Project concept relies on the solar window patented technology developed by PHYSEE at TRL6, and on the highly flexible PV technology of SUNPLUGGED, which will be further optimised and customised for Solar-Win application. Solar-Win will overcome a major barrier that presently limits a further deployment of BIPV solutions, which relates to its intrusive character. Moreover, Solar-Win will allow achieving a disruptive advance extending drastically the possibilities for integration of PV solutions to virtually any kind of buildings, just by installing and/or replacing building windows.

Keywords: solar windows,building integrated photovoltaics,thin film pv
Leveraging room temperature diamond quantum dynamics to enable safe, first-of-its-kind, multimodal cardiac imaging (MetaboliQs)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Tackling grand interdisciplinary science and technology challenges
Action type: Research and Innovation actions
Countries involved: Germany,Israel,Germany,Germany,Switzerland,United Kingdom
Call: FET Flagship on Quantum Technologies (H2020-FETFLAG-2018-03, 2018)
Start date: 2018-10-01
End date: 2022-03-31
Duration (months): 42.0
Total project cost (EUR): 6667801.25
EU funding (EUR): 6667801.25
Participants: 7
Project status: CLOSED

Cardiovascular Diseases (CVDs) are the number 1 cause of death globally: more people die annually from CVDs than from any other cause. Despite emerging diagnostics tools and therapeutics, several areas of significant unmet need remain unaddressed among CVD patients. The ability to personalize cardiovascular medical care and improve outcomes, will require characterization of disease processes at a molecular level. The current state-of-the-art, e.g., Positron emission tomography (PET), does not provide detailed information about the chemical state of the tissue at a molecular level, therefore it remains difficult to accurately diagnose and confidently select appropriate therapy in many circumstances. The MetaboliQs project brings together two areas of European excellence - diamond-based quantum sensing and medical imaging. We will translate a newly developed hyperpolarization method for magnetic resonance imaging (MRI) based on the quantum dynamics of nitrogen-vacancy (NV) centers. This breakthrough quantum technology will enable previously unachievable, highly sensitive quantification of metabolic activity, paving the way for precision diagnostics and better personalized treatment of cardiovascular and other metabolic diseases. For realizing and eventually commercializing the technology, MetaboliQs brings together a world-class multidisciplinary consortium with end to end expertise - leading diamond quantum technology research institutes (Fraunhofer IAF - quantum-grade diamond growth and fabrication, HUJI - quantum sensing) and innovative companies (Element 6 - worldwide leader in synthetic diamonds, NVision - inventor of diamond-based polarization), as well as two expert users of hyperpolarized and cardiovascular MRI (TUM, ETH Zurich - first in continental Europe to conduct clinical trials of hyperpolarized MRI for cardiovascular disease) and the market leader in electron paramagnetic resonance and preclinical MRI (Bruker).

Keywords: diamond quantum dynamics,hyperpolarisation,metabolic imaging,precision diagnostics,cardiovascular diseases
Optimal use of healthcare resources through AI-guided support of healthcare professionals (Medical Express)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Sweden
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2019)
Start date: 2019-12-01
End date: 2021-11-30
Duration (months): 24.0
Total project cost (EUR): 2708362.5
EU funding (EUR): 1895853.75
Participants: 1
Project status: TERMINATED

MedicalExpress (ME) is an AI-based innovation that optimises patient flow processes. It is a B2B solution for healthcare providers, developed to generate added value for patients and caregivers alike. ME is the result of 10 years of R&D together with clinicians, nurses and input from collaborators from academia, IT and pharma (e.g. Yale, Johns Hopkins, UCLA, ETH Zurich, Novo Nordisk and Sigma).electo ME is currently implemented in 30% of Sweden’s public primary care, where is has proven to allow each general practitioner (GP) to see 50% more patients/day, generating cost savings on the order of €100 000 per GP/year. By increasing efficiency, ME increases access to care, improves patient safety and generates cost savings not only for payers, but also by decreasing work absenteeism. Our offer is completely unique and the only CE-marked solution of its kind in Europe. ME is a comprehensive modular platform, which seamlessly integrates into existing IT structures and EHR (electronic health records). Being modular, ME can be fully customised to meet specific client needs. ME doesn’t replace jobs and retains diagnostic decision-making with experienced healthcare professionals. Our AI augments personnel in compiling and analysing data, creating reports and supporting decision-making in a way that liberates vital time that can be spent on tending after the patients. Having won several public tenders in competitions with international e-Health providers, we have demonstrated ME to be a great market fit as well as the most attractive solution to the prevailing resource management problem. In the project, we will roll out the solution for several new market segments and launch or product throughout Europe and the US. The project will take our market-validated solution through a rapid market replication phase that will create >20 new jobs in the EU alone. 5 years after having penetrated into new market segments, we anticipate revenues on the order of €35M.

Keywords: electronic health records,health informatics,patient workflow
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Preventing disease
Action type: Research and Innovation actions
Countries involved: Germany,Austria,Germany,Germany,Germany,Spain,Spain,Italy,Uganda,Switzerland,Switzerland,Switzerland,Switzerland,Belgium,Sweden,Switzerland,Côte d'Ivoire,Tanzania, United Republic of,Finland,France,France,France,France,France,Netherlands,United States,Netherlands,Netherlands,Netherlands,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,Mozambique
Call: PHC 9 – 2015: Vaccine development for poverty-related and neglected infectious diseases: HIV/AIDS (H2020-PHC-2015-single-stage_RTD, 2015)
Start date: 2016-01-01
End date: 2023-12-31
Duration (months): 96.0
Total project cost (EUR): 28224696.25
EU funding (EUR): 22188521.75
Participants: 49
Project status: SIGNED

Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses, 2. Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile, 3. Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines, and 4. Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure. EHVA project has developed a global and innovative strategy which includes: a) the multidisciplinary expertise involving immunologists, virologists, structural biology experts, statisticians and computational scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a number of African leading scientists/programs which will foster the testing of future EHVA vaccines through EDCTP

Keywords: hiv prophylactic and therapeutic vaccine development,strong immunology and vriological platforms,innovative trial design,data integration
Externally Tuneable Separations for Membrane Reactors (TUNEMEM)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Products and processes engineering
Panel description: Product and process design, chemical, civil, environmental, mechanical, vehicle engineering, energy processes and relevant computational methods
Countries involved: United Kingdom
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2015-08-01
End date: 2018-02-28
Duration (months): 31.0
Total project cost (EUR): 789823.77
EU funding (EUR): 789823.77
Participants: 1
Project status: CLOSED

I will develop an all new type of reactor for pharmaceutical and chemical process applications – the ‘tuneable membrane reactor’. These contain ground-breaking conducting polymer composite membranes that will allow in-situ tuning of the molecular selectivity for both neutral and charged species through them. This is revolutionary: current state-of-the-art membranes can be electrically tuned for charged species only. The project is timely, developing a new technology that can give the EU a competitive advantage for our declining pharmaceutical and (petro)chemical manufacturing base and builds on my recent research innovations. To do this, my team of 3 PDRAs, 3 PhDs and I will develop unique stable polymer-polymer acid-nanoparticle composite membranes that can be externally electrically tuned to different pore sizes and/or molecular selectivity, uniquely tuning for neutral and charged species. We will characterise the chemical, physical and transport mechanisms responsible for the membrane tuneablity and relate these to transport models. We will then determine the feasibility of applying these unique tuneable membranes into membrane reactors, to allow in-situ external control of two key reactor parameters currently not possible: (1) Membrane fouling - membrane pore size/free volume and charge will be changed by applied potential allowing the fouling layer to be pushed off/through the membrane. (2) Precise external control of the reactant and product spectrum in the reactor by modifying species retention. By doing this, these tuneable membranes can be used to control the reaction rate, emissions and catalyst retention to maximise reaction rate and selectivity. This increases energy efficiency and emission control, helping the EU 20-20-20 environmental targets to be met. The overall impact applies beyond the project – we will be able to increase the control of membrane separations used worldwide, helping industries including food, water, healthcare and chemicals.

Keywords: stimuli responsive materials,membrane separations,polymer materials,membrane reactors,reactor engineering
Development of Public Sector Innovation Observatory (OPSI)

Framework: Horizon 2020 — Societal Challenges
Programme: Europe in a changing world - inclusive, innovative and reflective societies
Action type: Coordination and support actions
Countries involved: France
Call: Europe (H2020-Adhoc-2014-20, 2014)
Start date: 2016-01-15
End date: 2019-01-14
Duration (months): 36.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: CLOSED

The project implements the goals of the Horizon 2020 Work Program “Europe in a Changing World: inclusive, innovative and reflective societies” by 1. fostering theoretical and practical learning on innovative approaches; 2. enhancing the sharing of ideas and co-creation of innovative solutions; 3. building innovative capacity of public servants. The project consists of a combination of research activities (on system innovation, innovation life-cycle, innovation at sub-national level); Observatory of Public Sector Innovation platform enhancement to provide a useful and practical tool to OECD and EU innovators (network of innovation contact points, virtual innovation project support, onlien interactive toolbox); and initiatives to build capacities of public servants to generate innovation.

Keywords: observatory,public sector,innovation,platform
Towards Innovative Low Carbon SMEs (TWINN-LC-SMEs)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: Spain,Italy,United Kingdom
Call: peer learning of innovation agencies (H2020-INNOSUP-2014-5, 2014)
Start date: 2016-05-01
End date: 2017-04-30
Duration (months): 12.0
Total project cost (EUR): 50000.0
EU funding (EUR): 50000.0
Participants: 3
Project status: CLOSED

The objective of the proposed project is to create a Design Options Paper (DOP) for the implementation of a cross-sector innovation collaboration programme benefitting start-up SMEs in the cleantech sector. A twinning partnership between three partners of the Climate-KIC initiative in three different EU countries will be established. This partnership will execute peer learning of a model (Climate Innovation Exchange), which uses expertise from different sectors to improve the business support given to start-up SMEs to wishing to successfully enter low carbon innovations to the market. This will be achieved by the implementation of the Twinning Advanced methodology for the development of the Design Option Paper in order to facilitate the mutual learning between innovation agencies in a structured way. The best practice model – Climate Innovation Exchange - developed within the Climate-KIC Accelerator programme from the Climate-KIC UK will be transferred to the innovation agencies from Spain and Italy involved in the programme. The key driving forces for successful implementation of the programme in UK will be analysed, together with the transfer conditions, obstacles and possibilities concerning, in particular, the target groups for the programme and the process by which the programme operates. The practices developed with Accelerator programme in Spain and Italy will also be studied informing the design of even better practices for the SMEs support in UK. The core group of 6 peer-learners (2 from each innovation agency) will be established to observe transferred practices, analyse local conditions, create the strategy (DOP), provide peer-to-peer support for the implementation as well as draft deployment driven amendments to the DOP and execute dissemination of the results.

Keywords: low carbon practices,clean technologies,smes,start ups
The Flagship ERA-NET (FLAG-ERA II)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Tackling grand interdisciplinary science and technology challenges
Action type: ERA-NET Cofund
Partnership: FLAG-ERA II (ERA-NET)
Countries involved: Germany,Austria,Spain,Italy,Bulgaria,Greece,Hungary,Lithuania,Poland,Slovenia,Sweden,Türkiye,Belgium,Romania,Slovakia,Latvia,France,Netherlands,Netherlands,Portugal,Denmark,Portugal,United Kingdom
Call: Partnering environment for FET flagships (H2020-FETFLAG-01-2016, 2016)
Start date: 2016-12-01
End date: 2022-11-30
Duration (months): 72.0
Total project cost (EUR): 18941250.0
EU funding (EUR): 6052612.5
Participants: 29
Project status: CLOSED

FLAG-ERA, the Flagship ERA-NET, gathers national and regional funding organisation with the goal of supporting, together with the European Commission, the FET Flagship initiatives and more generally the FET Flagship programme. Most funding organisations in Europe participate, either directly or as associated members. FLAG-ERA contributes to the construction of the two Flagship initiatives on Graphene and Human Brain research, through a range of activities such as the launch of joint calls supporting transnational projects in synergy with the Flagships, contribution to the Flagship partnering framework, identification of potential partnering projects, information on funding opportunities for the Flagships, and networking events. The activities in FLAG-ERA are organised around periodic events gathering all stakeholders and structured in sessions dedicated to the various objectives and related tasks of the project. FLAG-ERA II is the second ERA-NET project, implemented as an ERA-NET Cofund, starting in December 2016 for a period of 6 years, following the first FLA-ERA ERA-NET project which lasted from October 2013 to November 2016.
The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies (N-IF)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Biotechnology
Action type: SME instrument
Countries involved: Sweden
Call: Dedicated support to biotechnology SMEs closing the gap from lab to market (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-12-01
End date: 2018-05-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

InfiCure Bio is a Swedish Life Science company that was founded in 2015 with the primary objective of developing and commercializing a proprietary model for preclinical efficacy testing of anti-inflammatory and anti-fibrotic drugs. Our key product, the N-IF mouse, is a unique animal model that spontaneously develops fibrosis which is preceded by chronic inflammation and exhibits the same course of fibrotic disease progression as in humans, a unique feature that has been an ultimate need demanded by the pharmaceutical industry for many years. There are no efficient therapies aimed against fibrotic diseases despite the high prevalence among the world population and the huge impact on human health. To date, drug development has been hampered due to the lack of good and reliable preclinical models that better resemble human fibrotic disease conditions. The N-IF mouse eliminates the problems of currently available animal models that are time-consuming, labour-intensive to induce fibrosis and have a low reproducibility. Its unique features will allow to shorten test protocols by 4-8 weeks, increase robustness of tests due to its 100% reproducibility and minimize the number of experimental animals needed. Reductions in experiment time and in mice numbers directly translate into a 25 - 50% decrease in the overall costs of preclinical testing of anti-fibrotic drugs. We have already technically validated the N-IF mouse as a model for liver fibrosis and have acquired two clients. The objective of the Phase 1 project is to conduct a feasibility study and prepare for further validation studies of the mouse model in order to establish the pathology of NASH, renal and pulmonary fibrosis that will be conducted as part of Phase 2, enlarging our pipeline models for fibrotic diseases and opening doors to new segments of the fibrotic diseases market.

Keywords: animal model,fibrotic diseases,anti fibrotic drug development